Background: The problem of predicting whether a drug combination of arbitrary orders is likely to induce adverse drug reactions is considered in this manuscript.
Introduction
Drug-Drug Interactions (DDIs) and the associated Adverse Drug Reactions (ADRs) represent a consistent detriment to the public health in the United States. DDIs have accounted for approximately 26% of the ADRs, occurred among 50% of the hospitalized patients [1] , and caused nearly 74,000 emergency room visits and 195,000 hospitalizations annually in the US [2] . Apart from these, because of the common practice of co-medication among elderly Americans, particularly co-medication of more than two drugs, the high-order drug-drug interactions and their associated ADRs have imposed significant scientific and public health challenges. The National Health and Nutrition Examination Survey [3] reports that more than 76% of the elderly Americans take two or more drugs every day. Another study [4] estimates that about 29.4% of elderly American patients take six or more drugs every day. However, for most of such high-order DDIs, their mechanisms are unknown.
In this manuscript, novel approaches to predicting whether high-order drug combinations are likely to induce ADRs are presented. The prediction problems are formulated as a binary classification problem and support vector machines (SVMs) are used for the prediction. Novel kernels over drug combinations of arbitrary orders are developed within the framework of SVMs. These kernels are constructed using drug comedication information to measure single drug similarities and graph matching on drug combination graphs to measure drug combination similarities. A comparison on the new kernels with other convolutional kernels and probabilistic kernels on drug combinations is also conducted. The experimental results demonstrate that the new kernels outperform the others and can accurately predict whether a drug combination is likely to induce ADRs of interest with an AUC value 0.912. To the best of our knowledge, this manuscript represents the first effort in predicting DDIs for drug combinations of arbitrary orders.
Background
Drug-drug interactions Significant research efforts have been dedicated to detect pairwise drug-drug interactions (DDIs) [5, 6] in recent years. Existing methods either extract DDI pairs mentioned in medical literature or Electronic Health Records (EHRs) [4] , or predict/score DDI pairs from various drug/target information [7] . While most of the existing DDI studies are focused on interactions between a pair of drugs (i.e., order-2 DDIs), understanding high-order DDIs and their associated ADRs has attracted increasing attention recently [2, 8] . These emerging methods on high-order DDI studies are largely focused on how to discover high-order DDIs through mining frequent itemsets (i.e., drug combinations) from EHRs efficiently. Most recent work also includes pattern discovery from directional highorder DDIs [9] and directional high-order DDI prediction [10] .
Graph matching
Graph matching is to find the optimal vertex correspondence between two graphs [11, 12] . Graph matching problems can be broadly classified into two categories. The first category is exact graph matching, which is to find the graph and subgraph isomorphisms so that the mapping of vertices between two graphs is bijective and edge-preserving (i.e., vertices connected by an edge in one graph are mapped to vertices in the other graph that are also connected by an edge). The second category is inexact graph matching, which allows errors (e.g., different types of matched vertices in attributed graphs) during matching, and thus it is to minimize the total errors in finding optimal graph matching. Typical algorithms for graph matching include spectral methods [13] , probabilistic methods [14] , tree search [15] , etc.
Definitions and notations
We use d i to represent a drug, and D k = {d 1 , d 2 , · · · , d k } to represent a combination of k drugs, where k is the number of unique drugs in D k (i.e., k = |D k |) and thus the order of D k . A drug combination D k is defined when the drugs and only the drugs in D k are taken simultaneously. There are no orderings among the drugs in a drug combination. When no ambiguity is raised, we drop the superscript k in D k and represent a drug combination as D. An event is referred to as a patient taking a drug combination. In addition, in this manuscript, all vectors (e.g., c) are represented by bold lower-case letters and all matrices (e.g., X) are represented by upper-case letters. Row vectors are represented by having the transpose superscript T , otherwise by default they are column vectors. Table 1 summarizes the important notations in the manuscript.
Methods
We formulate the problem of predicting whether highorder drug combinations induce a particular ADR as a binary classification problem, and solve the classification problem within the framework of kernel methods and support vector machines (SVMs). In this manuscript, we consider myopathy as the ADR in particular. The central concept of SVM-based classification methods is that "similar" instances are likely to share similar labels, and thus the key is to capture and measure the "similarities" among instances (i.e., drug combinations in our ADR prediction problem) via kernels. In the case of drug combinations, we hypothesize that if two drug combinations share similar pharmaceutical, pharmacokinetic and/or pharmacodynamic properties, they may induce similar ADRs. Therefore, the question boils down to effectively representing and measuring the similarities in terms of such properties. To this end, we develop various kernels over drug combinations. A key property of such kernels as will be discussed later is that they are able to deal with drug combinations of arbitrary orders. These kernels are constructed using single drug similarities, which incorporate various drug information that could relate to DDIs. Here we decompose the discussion on such kernels from three aspects: 1). single drug similarities (SDS) as in Section , 2). our new kernel based on matching similar drugs in drug combination graphs in Section , and 3). other convolutional kernels [16] in Section . Given these kernels, we further employ the freely available SVM-Light software to build up the binary classifiers and conduct our experiments based on such classifiers [17] .
Single drug similarities
We use two different approaches to measuring single drug similarities (SDS). The first approach measures single drug similarities based on their intrinsic properties that can be represented by their 2D structures [18] . The second approach measures the similarities in a more data-driven fashion based on the co-occurrence patterns among drugs.
SDS from drug 2d structures
A straightforward way to measure SDSs between two drugs is to look at their structures, which ultimately determine their physicochemical properties. We use Extended Connectivity Fingerprints (ECFP) [19] of length 2,048 to represent drug 2D structures. Each of the fingerprint dimensions corresponds to a substructure among the drugs of interest. The binary values in the fingerprints represent whether a drug has the corresponding substructure or not. We use a vector x i ∈ R 2048 to represent the fingerprint for drug d i . The SDS between two drugs from their 2D structures, denoted as SDS 2d , is calculated as the Tanimoto coefficient between their ECFP fingerprints [20] . Tanimoto coefficient between two sets is defined as follows,
where |S| is the cardinality of set S. Thus, SDS 2d is defined as
where {x i } represents the set of substructures that di has in its fingerprint x i .
SDS based on co-medications
We develop a new approach to measuring the SDS between two drugs by looking at whether they are often involved in co-medications with similar other drugs, respectively. The hypothesis is that drugs that are respectively taken together with other similar drugs may share similar therapeutic purposes and target similar therapeutic targets, and thus behave similarly in inducing ADRs. Such data-driven co-medication based SDSs have a potential advantage over SDS 2d in that they leverage the signals from ADRs information directly that may not be captured or explained by drug 2D structures or other features on individual drugs. Such co-medication based SDS is denoted as SDS cm . We use two vectors c i to construct c i instead of co-medication frequencies from all events with and without ADRs together is that the comedication patterns from the two types of events can be very different, and thus one unified co-medication vector for both of them could not necessarily capture discriminative information among drugs.
Drug combination kernels from graph matching
We formulate the problem of comparing drug combination similarities through matching drug combination graphs, and develop a graph-matching based kernel for drug combination similarities. Specifically, for a drug combination D p = {d p1 , dp2, · · · , dpk p }, we construct a complete graph G p of k p nodes, in which each node represents a drug in D p , and all the nodes are connected to one another. Thus, the similarity between drug combination D p and D q can be measured based on how G p and G q match to each other. In matching such graphs, we consider SDSs so that drugs that are similar to each other should be matched, and the graph matching procedure should maximize the overall SDSs from matched drugs. The underlying assumption is that if two drug combinations share similar drugs, they could have similar ADRs. Figure 1 illustrates the idea of complete graph matching for two drug combinations, in which the drugs connected by dash lines are matched between D p and D q . The similarity calculated from graph matching over two drug combinations, denoted as S gm , will the sum of SDSs from matched drugs. S gm will be further converted to a valid kernel, denoted as K gm .
Graph matching algorithm for K gm The drug combination graph matching problem can be solved as a well known linear sum assignment problem (LSAP) [21] . The objective is to minimize the total cost of matching vertices in two graphs, and thus to find the graph matching with minimal total cost. In the case of high-order drug combinations, we define the cost of matching two drugs d i and d j as the dissimilarity between the drugs, that is,
where cost(d i , d j ) is the cost between d i and d j , SDS can be either SDS 2d or SDS cm . Thus, if two drugs are very similar (i.e., large SDS), the cost of matching them will be small and therefore they are more likely to be matched. Therefore, the graph matching can be solved by solving the following LSAP problem:
subject to X ∈ P,
where trace() is the trace of a matrix; and k p and k q are the number of vertices in G p and G q (and thus the order of D p and D q ), respectively;
is the pairwise drug-matching cost matrix for two drug combinations D p and
In Problem 4, X is the assignment matrix to match G p and G q (i.e., to assign a vertex in G p to a vertex in G q ), in which all the values are either 0 or 1, both the row sum and the column sum are either 0 or 1 (i.e., a vertex is either matched or not; if it is matched, it is matched to only one vertex in the other graph), and thus the sum of all the values is exactly the minimal of k p and k q (i.e., the vertices in the small graph have to be all matched). Essentially, X assigns each of the vertices in the smaller graph of G p and G q to exactly one vertex in the larger graph. The optimization problem in 4 can be solved by the Hungarian algorithm [22] . The drug-combination similarity S gm is then calculated as
where J ∈ R kp×kq is a matrix of all 1's. The drug-combination similarity matrix S gm is always symmetric but not necessarily positive semidefinite, and thus not always a valid kernel. To convert S gm to a valid kernel K gm , we follow the approach in Saigo et al. [23] . Specifically, we first conduct an eigenvalue decomposition on S gm , subtract from the diagonal of the eigenvalue matrix its smallest negative eigenvalue, and reconstruct the original matrix from the altered decomposition. The resulted matrix is positive, semi-definite, and is used as K gm .
Convolutional drug-combination kernels Drug combination kernels from common drugs
We define a drug-combination kernel, denoted as K cd , based on common drugs among drug combinations. K cd is calculated as the Tanimoto coefficient over the sets of drugs in the drug combinations, that is,
where Tanimoto() is defined as in Equation 1 . It has been proved that Tanimoto coefficient is a valid kernel function [24] . K cd essentially measures the proportion of shared common drugs among two drug combinations. The underlying assumption is that if two drug combinations share many common drugs, they are likely to have similar properties. To further enhance the similarity between two drug combinations from their common drugs, we also define an order-2 K cd of drug combinations, denoted as K (2) cd (K cd in Equation 6 is correspondingly referred to as order-1 K cd and denoted as K (1) cd ). We first represent a drug combination D = {d 1 , d2, · · · , dk} by all its single drugs and drug pairs, denoted as
cd on two drug combinations D p and D q can be calculated as the Tanimoto coefficient on D (2) p and D (2) q , that is,
Intuitively, K
cd better differentiates drug combinations with many shared drugs from those with fewer shared drugs than K (1) cd . We only extend K cd to order 2 since higher-order extension does not lead to better performance according to our experimental results. According to Equation 6 , when the order becomes much higher, Tanimoto(D
q ) may become very small due to a rapid combinatorial growth in the denominator and the insufficient common drug n-tuples (i.e., the number in the nominator). Thus, K cd with extension to much higher order may lose the ability to differentiate drug combinations that contain more common drugs.
Drug combination kernels from drug similarities
The drug combination similarities can also be measured by the average drug similarities. The hypothesis is that if two drug combinations have drugs that are similar on average, they may share similar properties. If two drug combinations have drugs that are similar on average, they may share similar properties. Therefore, we define an average-drug-similarity based kernel for drug combinations, denoted as K ds , as follows,
where k p and k q are the order of D p and D q , respectively, and SDS can be SDS 2d or SDS cm . Intuitively, K ds tends to capture averaged and smoothed drug combination similarities. It has been proved that as long as the involved SDSs are valid kernels (i.e., positive semi-definite), K ds will also be a valid kernel [16] .
Probabilistic drug combination kernels from drug sets
We apply an ensemble kernel for drug combinations based on the idea as in [25] . The key idea is to use a reproducing kernel to characterize sample similarities (i.e., SDS), and to use a probabilistic distance in the reproducing kernel Hilbert space (RKHS) to measure the ensemble similarity. The resulted ensemble similarity matrix is a valid kernel matrix, denoted as K pb . This ensemble involves an eigen value decomposition, during which, it is possible that some similarity matrices are deprecated numerically and it leads to defeats in K pb calculation. To deal with this issue, we increase the diagonals of involved square matrices by a small value to guarantee the positive semi-definite properties.
Materials

Mining drug combinations
We extract high-order drug combinations from FDA Adverse Event Reporting System (FAERS) [26] . We use myopathy as the ADR of particular interest, and extract 64,892 case (myopathy) events, in which patients report myopathy after taking multiple drugs, and 1,475,840 control (non-myopathy) events, in which patients do not report myopathy after taking drugs. Each of these events involves a combination of more than one drug. Among all the involved drug combinations, 10,250 unique drug combinations appear in both case and control events. For those 10,250 drug combinations, we use Odds Ratio (OR) to quantify their ADR risks. The OR for a drug combination D is defined based on the contingency table 2, that is, it is the ratio of the following two values: 1). the odds that the ADR occurs when D is taken (i.e., n1 m1 in Table 2 ); and 2). the odds that the ADR occurs when D is not taken (i.e., n2 m2 in Table 2 ). OR < 1 indicates the decreased risk of ADR after a patient takes the drug combination, OR = 1 indicates no risk change, and OR > 1 indicates the increased risk. In the 10,250 drug combinations, 8,986 combinations have OR > 1 and 1,264 combinations have OR < 1. These two sets of drug combinations are denoted as M 0 and N 0 , respectively. In addition to these combinations, there are 27,387 unique drug combinations that only appear in case events and 621,449 unique drug combinations that only appear in control events. These two sets are denoted as M + and N − , respectively. The set of drug combinations in case events is denoted as M (i.e., M = M + ∪ M 0 ), and the set of drug combinations in control events is denoted asN (i.e., N = N − ∪N 0 ). All these four sets together define a high-order drug combination dataset from FAERS, denoted as D FAERS . Table 3 presents the statistics of D FAERS .
Training data generation
As shown in Table 3 [27] . This set of 71 drugs is denoted as D Myo .
Evaluation protocol and metrics
The performance of the different methods is evaluated through five-fold cross validation. The dataset is randomly split into five folds of equal size (i.e., same number of drug combinations). Four folds are used for model training and the rest fold is used for testing. This process is performed five times, with one fold for testing each time. The final result is the average out of the five experiments.
We use accuracy, precision, recall, F1 and AUC to evaluate the performance of the methods. Accuracy is defined as the fraction of all correctly classified instances (i.e., true positives and true negatives) over all the instances in the testing set. Precision is defined as the fraction of correctly classified positive instances (i.e., true positives) over all instances that are classified as positive instances (i.e., true positives and false positives). Recall is the fraction of correctly classified positive instances (i.e., true positives) over all positive instances in the testing set (i.e., true positives and false negatives). F1 is the harmonic mean of precision and recall. AUC score is the normalized area under the curve that plots the true positives against the false positives for different thresholds for classification [28] . Larger accuracy, precision, recall, F1 and AUC values indicate better classification performance. Table 4 presents the performance comparison among the four different kernels in combination with different single drug similarities on dataset D * . Kernel K gm with SDS cm outperforms others in three (i.e., accuracy, F1 and AUC) out of five evaluation metrics. Specifically, in accuracy, K gm with SDS cm outperforms the second best kernel K gm with SDS 2d at 0.84%. In F1, K gm with SDS cm outperforms the second best kernel K gm with SDS 2d and K ds with SDS cm at 0.98%. In AUC, K gm with SDS cm outperforms the second best kernel order-2 K cd at 0.33%. In precision and recall, K gm with SDS cm is the second best kernel, whereas K ds with SDS cm and K ds with SDS 2d , respectively, is the best one. Overall, K gm with SDS cm has the best performance compared to other kernels. This indicates that it is effective to classify drug combinations by representing and comparing them as graphs (i.e., a set of drugs and their co-medication relation within the set), and measuring such graph similarities using their optimal matching (i.e., the optimal correspondence among drugs). In the following discussion, we use K cm gm to represent K gm with SDS cm . More experimental results on other datasets are available in the supplementary materials (see Additional file 1). Table 4 shows that SDS cm on average outperforms SDS 2d across different kernels (with a few exceptions on in precision for K ds and K pb ). SDS 2d considers drug intrinsic 2D structures. However, drug efficacy and side effects are the results of many complicated interactions and processes among drugs and various bioentities, which may not be sufficiently explained only by drug 2D structures. Compared to SDS 2d , SDS cm measures drug similarity based on their co-medication patterns, which could be regarded as a high-level abstraction and representation of drug therapeutic properties that may or may not be explicitly explained by each drug and its intrinsic properties independently.
Results
Overall performance
SDS performance
In K cd , order-2 representation (i.e., in K
cd ) for drug combinations outperforms order-1 representation (i.e., in K (1) cd ). In order-2 representation, in addition to single drugs, drug pairs are also used as a feature for a drug combination, which stresses the signals in drug combinations. This also conforms to common observations in other applications [29] , in which higher-order features improve classification performance. Figure 2 and 3 present the K cm gm prediction values with respect to drug combination orders. In Figure 2 , M + drug combinations have higher orders (on average 7.615 as in Table 3 ), and higher and mostly positive prediction values, while N − drug combinations have lower orders (on average 2.678), and lower and mostly negative prediction values. Meanwhile, the misclassification typically happens on N − drug combinations of higher orders, and on M + drug combinations of lower orders. Similar trends apply for M 0 and N 0 in Figure 3 . This indicates that K gm and SDS cm together are able to learn and make predictions that correspond to drug combination orders. In addition, drug combination order is correlated with their ADR labels. Figure 4 presents the K cm gm prediction values with respect to drug combination frequencies for M + and N − . M + drug combinations have lower frequencies (on average 5.520 as in Table 3 ), and higher and mostly positive prediction values, while N − drug combinations have higher frequencies (on average 42.082), and lower and mostly negative prediction values. For N − , the mis-classification typically happens on lowerfrequency drug combinations (the mis-classification for M + does not show strong patterns with respect to drug combination frequencies). As for M + and N − , drug combination frequencies are used to define ADR labels. Figure 4 shows that K cm gm together are able to learn and make predictions that correspond to drug combination frequencies and thus ADR labels. Table 5 presents the average percentage of D Myo drugs among all the drug combinations. For each drug combination, the percentage is calculated as the number of its drugs that can cause myopathy on their own (i.e., drugs in D Myo ) divided by the drug combination order. As Table 5 shows, top-10 mis-classified N drug combinations (i.e.,Ñ 10+ ) have almost twice as many D Myo drugs (30.7%) as those in N (15.6%), and even more than those in M drug combinations (24.3%). In addition, mis-classified N drug combinations (i.e.,Ñ + ) also have significantly more D Myo drugs (18.6%) than those in N (15.6%). Since K cm gm matches similar drugs, high D Myo drug enrichment could be a primary reason for the mis-classification.
Classification
D Myo drug enrichment
Top predictions
Top mis-classification on N Table 6 lists the top-10 (in terms of prediction values) drug combinations in N (i.e., without myopathy) that are mis-classified as positive (i.e., with myopathy) by K cm gm . For those drug combinations which appear in N 0 , we present their OR values, otherwise only frequencies. Those top mis-classified N drug combinations contain many single drugs, which on their own can induce myopathy (i.e., in D Myo , bold in Table 6 ). As a matter of fact, the percentage of D Myo drugs in top mis-classified N drug combinations is significantly higher than average. In Table 6 , one special mis-classified N drug combination is {lansoprazole omeprazole pantoprazole rabeprazole}, which does not contain any D Myo drugs. This set of drugs is commonly used as proton pump inhibitors (PPIs) to decrease the amount of acid produced in the stomach. Some case studies show evidence of causality between the PPI drug class and myopathy [30, 31] .
Top prediction on M Table 7 presents the top-10 correctly predicted M drug combinations by K cm gm . These drug combinations are significantly enriched with D Myo drugs (i.e., drugs that can induce myopathy on their own). As Table 5 shows, M 10+ has the most D Myo drugs (89.8%) compared to all the other sets and significantly more than M. In particular, all of these combinations contain statin drugs (e.g., atorvastatin, simvastatin and rosuvastatin, etc.). These statin-related drugs have been studied in literature as a drug class that has high possibilities to induce myopathy [32, 33] . In addition, in Table 7 , 4 out of the 6 M 0 drug combinations among top 10 (i.e., the drug combinations that have OR values) have their OR values higher than average in M 0 (31.998 as in Table 3 ), and 3 out of the 4 M + drug combinations among top 10 (i.e., the drug combinations that do not have OR values) have their frequency higher than average in M + (5.520 as in Table 3 ). In addition, among the top-20 drug combinations predicted by K Table 3 ). The 3 drug combinations from M + in this table have their frequency lower than the average in M + (5.520 as in Table 3 ) but very close. In Table 8, 8 out of top-10 drug combinations include alendronate. Case studies demonstrate that several events of severe muscle pain, which is the common symptom of myopathy, were reported after patients started therapy with alendronate [34] , showing the association between the medical treatment with alendronate and myopathy.
Discussions
The experimental results show that the new methods with drug co-medication based single drug similarities outperform other kernels, such as convolutional kernels [16] and probabilistic kernels [25] , and can accurately predict whether a drug combination is likely to induce ADRs of interest. The experimental results demonstrate the advance of such single drug similarities that leverage co-medication patterns among highorder drug-drug interactions, and also inspire further exploration that learns such similarities in a pure datadriven fashion without pre-defined kernels, for example, via manifold learning. Further research would also include learning drug representations in a data-driven fashion such that the representations better quantify drug similarities in terms of their co-medication patterns. Deep learning would be an optimistic option for such drug representation learning.
Conclusions
In this manuscript, SVM-based classification methods were developed to predict whether a drug combination of arbitrary orders is likely to induce adverse drug reactions. Novel kernels over drug combinations of arbitrary orders were developed for such classification. These kernels were constructed from various single-drug information including drug co-medication patterns, and compare drug combination similarities based on single drugs they have and the relations among the single drugs. Specifically, a novel kernel over drug combinations of arbitrary orders was developed based on graph matching over drug combination graphs. A dataset from FDA Adverse Event Reporting System (FAERS) was constructed to test the new methods. The experimental results demonstrated that the new methods with drug co-medication based single drug similarities and graph matching based kernels achieve the best AUC as 0.912. The prediction also revealed strong patterns among drug combinations (e.g., statin enriched) that may be highly correlated with their induced ADRs.
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In the table, n 1 is the number of events where D is taken with ADR occurring; m 1 is the number of events where D is taken without ADR occurring; n 2 is the number of events where D is not taken with ADR occurring; and m 2 is the number of events where D is not taken without ADR occurring, respectively. In this table, "#{D}" and "#{d}" represent the number of drug combinations and the number of involved drugs, respectively. In each set of drug combinations, "avgOrd" is the the average order; "avgFrq" is the average frequency; and "avgOR" represents the average OR. In this table, "acc", "pre", "rec", "F1" and "AUC" represent accuracy, precision, recall, F1 and the area under an receiver operating characteristic curve, respectively. K cd with "ord-1" corresponds to K (1) cd , and K cd with "ord-2" corresponds to K (2) cd . In this table, "acc", "pre", "rec" and "AUC" represent accuracy, precision, recall, and the area under an receiver operating characteristic curve, respectively. In K cd , "ord-1" is the kernel, in which the similarity between two drug combinations is calculated by the feature vectors, whose dimensions correspond to only one drug. As for "ord-2", the similarity between two drug combinations is calculated by the feature vectors, which have dimensions that correspond to different pairs of drugs.
SDS cm outperforms the second best kernel K gm with SDS 2d at 0.97% and 0.33% in D 2000 and D 4000 , respectively. In recall, K gm with SDS cm outperforms the second best kernel K gm with SDS 2d at 1.55% and 0.12% in D 2000 and D 4000 , respectively. In F1, K gm with SDS cm outperforms the second best kernel K gm with SDS 2d at 1.08% and 0.34% in D 2000 and D 4000 , respectively. In AUC, K gm with SDS cm outperforms the second best kernel K gm with SDS 2d at 0.31% in D 2000 and outperforms the second best kernel ord-2 K cd at 0.42% in D 4000 . In precision, the best kernel K gm with SDS cm outperforms the second best kernel K ds with SDS 2d at 0.21% in D 2000 , whereas the best kernel K ds with SDS 2d outperforms the second best kernel K gm with SDS cm at 0.53% in D 4000 . In three datasets, D 2000 , D 4000 and D * , in general, K gm with SDS cm has the best performance compared to other kernels with a few exceptions. This may show the effectiveness to classify drug combinations by measuring the similarities between graphs, which represent drug combinations.
In kernel K gm and K pb , SDS cm outperforms SDS 2d on average. This indicates the consistency in three datasets of better capability to measure the similarities based on co-medication patterns than drug 2D structures. For kernel K cd , ord-2 outperforms ord-1 in both datasets as in D * . This consists with our observation before. That is, the ord-2 representation, which contains drug pairs as a feature, can emphasize the co-occurrence patterns in drug combinations.
